EP2013170B1 - Dérivés de 4-squarylpipérazine utilisés en tant qu'agents antiviraux - Google Patents
Dérivés de 4-squarylpipérazine utilisés en tant qu'agents antiviraux Download PDFInfo
- Publication number
- EP2013170B1 EP2013170B1 EP07761192A EP07761192A EP2013170B1 EP 2013170 B1 EP2013170 B1 EP 2013170B1 EP 07761192 A EP07761192 A EP 07761192A EP 07761192 A EP07761192 A EP 07761192A EP 2013170 B1 EP2013170 B1 EP 2013170B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- aids
- hiv
- ene
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 0 CC(CC(C(C1=O)N(CC2)CCC2C(C(C2=CNC3=CCCC(C)=C23)=O)=O)C1=*)C1=CCCCC1 Chemical compound CC(CC(C(C1=O)N(CC2)CCC2C(C(C2=CNC3=CCCC(C)=C23)=O)=O)C1=*)C1=CCCCC1 0.000 description 8
- IZYDPWHWZPIRAZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C1=O)=O)=C1c(cc1)ccc1F)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C1=O)=O)=C1c(cc1)ccc1F)=O IZYDPWHWZPIRAZ-UHFFFAOYSA-N 0.000 description 1
- DBPMWRYLTBNCCE-UHFFFAOYSA-N COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2OC Chemical compound COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2OC DBPMWRYLTBNCCE-UHFFFAOYSA-N 0.000 description 1
- ZNBAMNXZJNZNGC-UHFFFAOYSA-N COc1c(c(C(C(N(CC2)C3(CC3)CN2C(c2ccccc2)=O)=O)=O)c[nH]2)c2ncc1 Chemical compound COc1c(c(C(C(N(CC2)C3(CC3)CN2C(c2ccccc2)=O)=O)=O)c[nH]2)c2ncc1 ZNBAMNXZJNZNGC-UHFFFAOYSA-N 0.000 description 1
- MHTMPARRAWTWLJ-CQSZACIVSA-N C[C@H](CN(CC1)C(C(C2=O)=O)=C2c2ccccc2)N1C(C(c1c[nH]c2c1c(OC)cnc2OC)=O)=O Chemical compound C[C@H](CN(CC1)C(C(C2=O)=O)=C2c2ccccc2)N1C(C(c1c[nH]c2c1c(OC)cnc2OC)=O)=O MHTMPARRAWTWLJ-CQSZACIVSA-N 0.000 description 1
- FKRRABHXUWVCEV-UHFFFAOYSA-N O=C(C(Cl)=O)c1c[nH]c2cccc(F)c12 Chemical compound O=C(C(Cl)=O)c1c[nH]c2cccc(F)c12 FKRRABHXUWVCEV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use.
- the disclosure is concerned with 4-squarylpiperazine derivatives that possess unique antiviral activity.
- the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
- HIV-1 human immunodeficiency virus -1 infection
- HIV-1 human immunodeficiency virus -1 infection
- RT nucleoside reverse transcriptase
- AZT or Retrovir ® didanosine
- Videx ® stavudine
- lamivudine lamivudine
- zalcitabine or DDC or Hivid ®
- abacavir succinate or Ziagen ®
- Tenofovir disoproxil fumarate salt or Viread ®
- emtricitabine or FTC
- Combivir ® contains -3TC plus AZT
- Trizivir ® contains abacavir, lamivudine, and zidovudine
- Epzicom ® contains abacavir and lamivudine
- Truvada ® contains Viread ® and emtricitabine
- novel anti-HIV agents exhibiting distinct resistance patterns, and favorable pharmacokinetic as well as safety profiles are needed to provide more treatment options.
- Improved HIV fusion inhibitors and HIV entry coreceptor antagonists are two examples of new classes of anti-HIV agents currently being studied by a number of investigators.
- HIV attachment inhibitors The properties of a class of HIV entry inhibitors called HIV attachment inhibitors has been improved in an effort to obtain compounds with maximized utility and efficacy as antiviral agents.
- a piperazine amide (In these three structures a piperazine phenyl amide) is present and this group is directly attached to an oxoacetyl moiety.
- the oxoacetyl group is attached at the 3-position of 4-Fluoro indole in BMS-705 and to the 3 position of substituted azaindoles in BMS-806 and BMS-043.
- piperazine amide portion of the molecules have also been described in the art and among these examples are (1) some piperidine alkenes; (2) some pyrrolidine amides; (3) some N-aryl or heteroaryl piperazines; (4) some piperazinyl ureas; and (5) some carboline containing compounds.
- WO2005/016344 and W02005/121094 also describe piperazine derivatives which are HIV inhibitors.
- the compounds described in these applications are structurally distinct from the compounds of the present disclosure.
- WO 02/04440 discloses substituted indoleoxoacetic piperazine derivatives possessing antiviral activity, alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV. entry inhibitors, particularly realting to the treatment of HIV or Aids.
- the present disclosure relates to compounds of Formula I, the pharmaceutically acceptable salts and/or solvates (e.g., hydrates) thereof, their pharmaceutical formulations, and these compounds for use in patients suffering from or susceptible to a virus such as HIV.
- the compounds of Formula I, their pharmaceutically acceptable salts and/or solvate are effective anticiral agents, particularly as inhibitors of HIV. They are useful for the treatment of HIV and AIDS.
- One embodiment of the disclosure relates to a compound of Formula I, or pharmaceutically acceptable salts thereof, wherein :X is CH or N; R' is F or methoxy; R 2 is hydrogen, methoxy, Cl, Br, or heteroaryl selected from the group consisting of triazolyl, pyrazolyl and pyrazine, wherein said heteroaryl is optionally substituted with one or two of the same or different members selected from the group consisting of amino, nitro, cyano, hydroxy, C 1-6 alkoxy, -C(O)NH 2 , C 1-6 alkyl, -NHC(O)CH 3 , halogen, and trifluoromethyl; R 3 is H or methyl; R 4 is H or methyl; R 5 is C 1-4 alkyl, phenyl, furyl, thienyl, benzothienyl, thiazolyl, imidazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, benzothiazo
- Another embodiment of the present disclosure is a compound of Formula I, and one or more pharmaceutically acceptable carriers, excipients or diluents for use in treating mammals infected with a virus, especially wherein said virus is HIV.
- the compound of Formula I can be administered in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) HIV entry inhibitors.
- Another embodiment of the present disclosure is a pharmaceutical composition
- a pharmaceutical composition comprising an antiviral effective amount of a compound of Formula I and one or more pharmaceutically acceptable carriers, excipients, diluents and optionally in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) HIV entry inhibitors.
- an AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) HIV entry inhibitors.
- the present disclosure includes the individual diastereoisomeric and enantiomeric forms of the compounds of Formula I in addition to the mixtures thereof.
- C 1-6 alkyl as used herein and in the claims (unless specified otherwise) mean straight or branched chain alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, amyl, hexyl and the like.
- Halogen refers to chlorine, bromine, iodine or fluorine.
- heteroaryl refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms selected from the group consisting of nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi-electron system. Unless otherwise indicated, the heteroaryl group may be attached at either a carbon or nitrogen atom within the heteroaryl group. It should be noted that the term heteroaryl is intended to encompass an N-oxide of the parent heteroaryl if such an N-oxide is chemically feasible as is known in the art.
- Heteroaryl groups are furyl, thienyl, benzothienyl, thiazolyl, imidazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, benzothiazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, pyrrolyl, pyranyl, tetrahydropyranyl, pyrazolyl, pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl, carbazolyl, benzoxazolyl, benzimidazolyl, indolyl, isoindolyl, pyrazinyl. diazinyl, pyrazine, triazinyl, tetrazinyl, and tetrazolyl.
- cycloalkyl group refers to an all-carbon monocyclic or fused ring (i.e., rings which share and adjacent pair of carbon atoms) group wherein one or more rings does not have a completely conjugated pi-electron system.
- examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane and cyclohexadiene.
- a "hydroxy” group refers to an -OH group.
- alkoxy refers to both an -O-alkyl and an -O-cycloalkyl group as defined herein.
- amino refers to an -NH 2 group.
- a "cyano" group refers to a -CN group.
- nitrogen atoms in heteroaryl systems can be "participating in a heteroaryl ring double bond", and this refers to the form of double bonds in the two tautomeric structures which comprise five-member ring heteroaryl groups. This dictates whether nitrogens can be substituted as well understood by chemists in the art.
- the disclosure and claims of the present disclosure are based on the known general principles of chemical bonding. It is understood that the claims do not encompass structures known to be unstable or not able to exist based on the literature.
- Physiologically acceptable salts and prodrugs of compounds disclosed herein are within the scope of this disclosure.
- pharmaceutically acceptable salt as used herein and in the claims is intended to include nontoxic base addition salts. Suitable salts include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, tartaric acid, lactic acid, sulfinic acid, citric acid, maleic acid, fumaric acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, and the like.
- salts of acidic groups such as a carboxylate
- counterions such as ammonium, alkali metal salts, particularly sodium or potassium, alkaline earth metal salts, particularly calcium or magnesium
- suitable organic bases such as lower alkylamines (methylamine, ethylamine, cyclohexylamine, and the like) or with substituted lower alkylamines (e.g. hydroxyl-substituted alkylamines such as diethanolamine, triethanolamine or tris(hydroxymethyl)- aminomethane), or with bases such as piperidine or morpholine.
- antiviral effective amount means the total amount of each active component that is sufficient to show a meaningful patient benefit, i.e., healing of acute conditions characterized by inhibition of the HIV infection.
- a meaningful patient benefit i.e., healing of acute conditions characterized by inhibition of the HIV infection.
- the term refers to that ingredient alone.
- the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
- the terms "treat, treating, treatment” as used herein and in the claims means preventing or ameliorating diseases associated with HIV infection.
- the present disclosure is also directed to combinations of the compounds with one or more agents useful in the treatment of AIDS.
- the compounds of this disclosure may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, antiinfectives, or vaccines, such as those in the following table.
- AIDS, ARC HIV positive asymptomatic ddC Dideoxycytidine Hoffman-La Roche HIV infection, AIDS, ARC ddI Dideoxyinosine Bristol-Myers Squibb HIV infection, AIDS, ARC; combination with AZT/d4T DMP-450 AVID (Camden, NJ) HIV infection, AIDS, ARC (protease inhibitor) Efavirenz (DMP 266, Sustiva ® ) (-)6-Chloro-4-(S)-cyclopropylethynyl-4(S)-trifluoro-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-one, STOCRINE Bristol Myers Squibb HIV infection, AIDS, ARC (non-nucleoside RT inhibitor) EL10 Elan Corp, PLC (Gainesville, GA) HIV infection Famciclovir Smith Kline herpes zoster, herpe
- HIV infection HIV, AIDS, ARC Recombinant Human Interferon Beta Triton Biosciences (Almeda, CA) AIDS, Kaposi's sarcoma, ARC Interferon alfa-n3 Interferon Sciences ARC, AIDS Indinavir Merck HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC ISIS 2922 ISIS Pharmaceuticals CMV retinitis KNI-272 Nat'l Cancer Institute HIV-assoc.
- Lamivudine 3TC Glaxo Wellcome HIV infection, AIDS, ARC (reverse transcriptase inhibitor); also with AZT Lobucavir Bristol-Myers Squibb CMV infection Nelfinavir Agouron Pharmaceuticals HIV infection, AIDS, ARC (protease inhibitor) Nevirapine Boeheringer Ingleheim HIV infection, AIDS, ARC (RT inhibitor) Novapren Novaferon Labs, Inc. (Akron, OH) HIV inhibitor Peptide T Octapeptide Sequence Peninsula Labs (Belmont, CA) AIDS Trisodium Phosphonoformate Astra Pharm. Products, Inc.
- the compounds of the disclosure herein may be used in combination with another class of agents for treating AIDS which are called HIV entry inhibitors.
- HIV entry inhibitors are discussed in DRUGS OF THE FUTURE 1999, 24(12), pp. 1355-1362 ; CELL, Vol. 9, pp. 243-246, Oct. 29, 1999 ; and DRUG DISCOVERY TODAY, Vol. 5, No. 5, May 2000, pp. 183-194 and Inhibitors of the entry of HIV into host cells. Meanwell, Nicholas A.; Kadow, John F. Current Opinion in Drug Discovery & Development (2003), 6(4), 451-461 .
- the compounds can be utilized in combination with other attachment inhibitors, fusion inhibitors, and chemokine receptor antagonists aimed at either the CCR5 or CXCR4 coreceptor.
- Preferred combinations are simultaneous or alternating treatments with a compound of the present disclosure and an inhibitor of HIV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase.
- An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddI.
- a preferred inhibitor of HIV protease is Reyataz ® (active ingredient Atazanavir). Typically a dose of 300 to 600mg is administered once a day. This may be co-administered with a low dose of Ritonavir (50 to 500mgs).
- Another preferred inhibitor of HIV protease is Kaletra ® .
- indinavir is the sulfate salt of N-(2(R)-hydroxy-1-(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999 .
- Indinavir is generally administered at a dosage of 800 mg three times a day.
- Other preferred protease inhibitors are nelfinavir and ritonavir.
- HIV protease is saquinavir which is administered in a dosage of 600 or 1200 mg tid.
- Preferred non-nucleoside inhibitors of HIV reverse transcriptase include efavirenz.
- the preparation of ddC, ddI and AZT are also described in EPO 0,484,071 . These combinations may have unexpected effects on limiting the spread and degree of infection of HIV.
- Preferred combinations include those with the following (1) indinavir with efavirenz, and, optionally, AZT and/or 3TC and/or ddI and/or ddC; (2) indinavir, and any of AZT and/or ddI and/or ddC and/or 3TC, in particular, indinavir and AZT and 3TC; (3) stavudine and 3TC and/or zidovudine; (4) zidovudine and lamivudine and 141 W94 and 1592U89; (5) zidovudine and lamivudine.
- the compound of the present disclosure and other active agents may be administered separately or in conjunction.
- the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
- Preferred combinations are simultaneous or alternating treatments of with a compound of the present disclosure and an inhibitor of HIV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase.
- An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddI.
- a preferred inhibitor of HIV protease is indinavir, which is the sulfate salt of N-(2(R)-hydroxy-1-(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide ethanolate, and is synthesized according to U.S. 5,413,999 .
- Indinavir is generally administered at a dosage of 800 mg three times a day.
- Other preferred protease inhibitors are nelfinavir and ritonavir.
- HIV protease is saquinavir which is administered in a dosage of 600 or 1200 mg tid.
- Preferred non-nucleoside inhibitors of HIV reverse transcriptase include efavirenz.
- the preparation of ddC, ddI and AZT are also described in EPO 0,484,071 . These combinations may have unexpected effects on limiting the spread and degree of infection of HIV.
- Preferred combinations include those with the following (1) indinavir with efavirenz, and, optionally, AZT and/or 3TC and/or ddI and/or ddC; (2) indinavir, and any of AZT and/or ddI and/or ddC and/or 3TC, in particular, indinavir and AZT and 3TC; (3) stavudine and 3TC and/or zidovudine; (4) zidovudine and lamivudine and 141 W94 and 1592U89; (5) zidovudine and lamivudine.
- the compound of the present disclosure and other active agents may be administered separately or in conjunction.
- the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
- the compounds of the present disclosure may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and diluents.
- the pharmaceutical composition may be in the form of orally administrable suspensions or tablets; nasal sprays, sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories.
- these compositions When administered orally as a suspension, these compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweetners/flavoring agents known in the art.
- these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents, and lubricants known in the art.
- the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
- the compounds of this disclosure can be administered orally to humans in a dosage range of 1 to 100 mg/kg body weight in divided doses.
- One preferred dosage range is 1 to 10 mg/kg body weight orally in divided doses.
- Another preferred dosage range is 1 to 20 mg/kg body weight in divided doses.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- the present disclosure comprises compounds of Formula I, their pharmaceutical formulations, and their use in patients suffering from or susceptible to HIV infection.
- the compounds of Formula I include pharmaceutically acceptable salts thereof.
- General procedures to construct compounds of Formula I and intermediates useful for their synthesis are described in the following Schemes.
- FT-1R Spectra were acquired using a Nicolet Protégé 460 spectrometer, with samples prepared as either thin films or KBr pellets.
- 3-isopropoxy-4-substituted-cyclobut-3-ene-1,2-diones were conveniently used as precursors, being prepared from either 3,4-diisopropoxy-cyclobut-3-ene-1,2-dione ( cf. L. S. Liebeskind, et al., J. Org. Chem. 1988, 53, 2482 ) or from 3-isopropoxy-4-(tri- n -butylstannyl)-cyclobut-3-ene-1,2-dione ( cf. L. S. Liebeskind, et al., J. Org. Chem. 1993, 58, 3543 ) according to methods well-documented in the literature.
- indole-3-(2-oxo)acetic acid derivatives were conveniently prepared by reacting an indole, as for example 4-fluoroindole, with oxalyl chloride in ether.
- the resulting acid chloride derivative was readily reacted with any of a series of 3-piperazinyl-4-substituted-cyclobut-3-ene-1,2-diones in the presence of a suitable amine base in an appropriate solvent, as for example diisopropylethylamine in dichloromethane, to afford the corresponding desired amide derivatives.
- the compounds B1-B8 were prepared.
- a suitable 4,7-disubstituted-6-azaindole-3-(2-oxo)acetic acid could be coupled with a 3-piperazinyl-4-substituted-cyclobut-3-ene-1,2-dione, by first preforming the acid chloride using conventional methodology and then performing the coupling step in the presence of a suitable amine base such as diisopropylethylamine.
- the coupling step could be effected directly with the acid using any of a number of well-known amide coupling reagents, as for example BOP-Cl, together with a suitable amine base such as diisopropylethylamine, in an appropriate solvent such as chloroform.
- amide coupling reagents as for example BOP-Cl
- a suitable amine base such as diisopropylethylamine
- the latter was saponified to the corresponding 6-azaindole-3-(2-oxo)acetic acid using an alkali metal base, such as K 2 CO 3 or NaOH, in a suitable mixture of a solvent such as methanol or dioxane and water.
- an alkali metal base such as K 2 CO 3 or NaOH
- the resulting acid was then most conveniently coupled with a 3-piperazinyl-4-substituted-cyclobut-3-ene-1,2-dione using any of a number of well-known amide coupling reagents, as for example BOP-Cl, together with a suitable amine base such as diisopropylethylamine, in an appropriate solvent such as chloroform.
- amide coupling reagents as for example BOP-Cl
- the resulting 7-halo-6-azaindole derived intermediate was then coupled with an appropriate coupling partner, as for example an arylstannane, using any of a number of well-known catalyzed cross-coupling methodologies, as for example one using a palladium catalyst in a suitable solvent such as dioxane, to give the desired 7-substituted-6-azaindole derivatives.
- an appropriate coupling partner as for example an arylstannane
- Virus -Single-round infectious reporter virus was produced by co-transfecting human embryonic Kidney 293 cells with an HIV-1 envelope DNA expression vector and a proviral cDNA containing an envelope deletion mutation and the luciferase reporter gene inserted in place of HIV-1 nef sequences ( Chen et al, Ref. 41 ). Transfections were performed using lipofectAMINE PLUS reagent as described by the manufacturer (Invitrogen, Carlsbad, CA).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Claims (10)
- Composé de formule I, ou un sel pharmaceutiquement acceptable de celui-ci,
R1 est F ou un groupe méthoxy;
R2 est un hydrogène, un groupe méthoxy, Cl, Br, ou un groupe hétéroaryle choisi dans le groupe constitué des triazolyle, pyrazolyle et pyrazine, ledit groupe hétéroaryle étant éventuellement substitué par un ou deux membres identiques ou différents de l'ensemble constitué par les groupes amino, nitro, cyano, hydroxy, alcoxy en C1-6, - C(O)NH2, alkyle en C1-6, -NHC(O)CH3, halogène, et trifluorométhyle;
R3 est H ou un groupe méthyle;
R4 est H ou un groupe méthyle;
R5 est un groupe alkyle en C1-4, phényle, furyle, thiényle, benzothiényle,
thiazolyle, imidazolyle, oxazolyle, oxadiazolyle, thiadiazolyle, benzothiazolyle, triazolyle, tétrazolyle, isoxazolyle, isothiazolyle, pyrrolyle, pyranyle, tétrahydropyranyle, pyrazolyle, pyridyle, pyrimidinyle, quinoléinyle, isoquinoléinyle, purinyle, carbazolyle, benzoxazolyle, benzimidazolyle, indolyle, isoindolyle, pyrazinyle, diazinyle, pyrazine, triazinyle, tétrazinyle, tétrazolyle, OR6 ou NR6R7;
R6 et R7 sont chacun indépendamment choisis dans le groupe constitué de H et des groupes alkyle en C1-C6 et cycloalkyle en C3-C6, lesdits groupes cycloalkyle en C3-C6 pouvant être condensés avec un phényle ou une pyridine; R6 et R7 peuvent éventuellement être réunis par un atome de C, O, N, S, atomes parmi lesquels les atomes de C et de N de jonction peuvent être substitués par un groupe alkyle en C1-C6, cycloalkyle en C3-C6 ou l'atome de C de jonction peut faire partie du groupe cycloalkyle en C3-C6. - Composé de la revendication 1 dans lequel
R5 est un groupe phényle ou thiényle;
R2 est un groupe méthoxy, chloro, bromo, pyrazinyle, triazolyle, ou pyrazolyle. - Composition pharmaceutique qui comprend une quantité antivirale efficace d'un composé de formule I, incluant des sels pharmaceutiquement acceptables de celui-ci, selon n'importe lesquelles des revendications 1 à 3, et un ou plusieurs véhicules, excipients, ou diluants, pharmaceutiquement acceptables.
- Composition de la revendication 4 comprenant en outre un second composé ayant une activité anti-VIH.
- Composition pharmaceutique de la revendication 4, destinée à être utilisée dans le traitement d'une infection par le VIH, qui comprend en outre une quantité antivirale efficace d'un agent de traitement du SIDA choisi dans le groupe constitué de:(a) un agent antiviral contre le SIDA;(b) un agent anti-infectieux;(c) un immunomodulateur; et(d) des inhibiteurs d'entrée du VIH.
- Composé de formule I tel que défini dans n'importe lesquelles des revendications 1 à 3 destiné à être utilisé en thérapeutique.
- Composé tel que défini dans la revendication 7, destiné à être utilisé dans le traitement d'un mammifère infecté par un virus.
- Composé destiné à être utilisé selon la revendication 8, le composé de formule I étant administré en association avec une quantité antivirale efficace d'un agent de traitement du SIDA choisi dans le groupe constitué de: un agent antiviral contre le SIDA; un agent anti-infectieux; un immunomodulateur; et un inhibiteur d'entrée du VIH.
- Composé destiné à être utilisé selon la revendication 8, ledit virus étant le VIH.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79469906P | 2006-04-25 | 2006-04-25 | |
PCT/US2007/067302 WO2007127731A1 (fr) | 2006-04-25 | 2007-04-24 | Dérivés de 4-squarylpipérazine utilisés en tant qu'agents antiviraux |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2013170A1 EP2013170A1 (fr) | 2009-01-14 |
EP2013170B1 true EP2013170B1 (fr) | 2012-06-27 |
Family
ID=38457647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07761192A Not-in-force EP2013170B1 (fr) | 2006-04-25 | 2007-04-24 | Dérivés de 4-squarylpipérazine utilisés en tant qu'agents antiviraux |
Country Status (3)
Country | Link |
---|---|
US (1) | US7501419B2 (fr) |
EP (1) | EP2013170B1 (fr) |
WO (1) | WO2007127731A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
PT2812332T (pt) | 2012-02-08 | 2017-11-15 | Viiv Healthcare Uk (No 4) Ltd | Métodos para a preparação do composto profármaco piperazina inibidor da conjugação ao vih |
AU2015364535A1 (en) * | 2014-12-18 | 2017-07-06 | Viiv Healthcare Uk (No. 4) Limited | A process for preparing halogenated azaindole compounds using PyBroP |
RU2017123259A (ru) | 2014-12-18 | 2019-01-21 | ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД | Способ получения галогенированных азаиндольных соединений с использованием бороксина |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004502768A (ja) * | 2000-07-10 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | 置換インドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性 |
WO2003103607A2 (fr) | 2002-06-11 | 2003-12-18 | Bristol-Myers Squibb Company | Dosage de fusion a mediation par enveloppe virale |
AU2004264724A1 (en) | 2003-08-14 | 2005-02-24 | Pfizer Inc. | Piperazine derivatives for the treatment of HIV infections |
US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US20050215543A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
WO2005121094A1 (fr) | 2004-06-09 | 2005-12-22 | Pfizer Limited | Derives de piperazine et de piperidine utilises comme agents anti-vih |
-
2007
- 2007-04-19 US US11/737,354 patent/US7501419B2/en not_active Expired - Fee Related
- 2007-04-24 WO PCT/US2007/067302 patent/WO2007127731A1/fr active Application Filing
- 2007-04-24 EP EP07761192A patent/EP2013170B1/fr not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
WO2007127731A1 (fr) | 2007-11-08 |
US7501419B2 (en) | 2009-03-10 |
EP2013170A1 (fr) | 2009-01-14 |
US20070249624A1 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2646439B1 (fr) | Amides d'alkyle comme inhibiteurs d'attachement du vih | |
EP1943221B1 (fr) | Amidines de pipérazine en tant qu agents antiviraux | |
US7504399B2 (en) | Piperazine enamines as antiviral agents | |
EP2303876B1 (fr) | Dicéto-azolopipéridines et azolopipérazines en tant qu'agents anti-vih | |
US7037913B2 (en) | Bicyclo 4.4.0 antiviral derivatives | |
US9156828B2 (en) | Tricyclic amidine derivatives as HIV attachment inhibitors | |
US8450361B2 (en) | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | |
EP2013170B1 (fr) | Dérivés de 4-squarylpipérazine utilisés en tant qu'agents antiviraux | |
US9505752B2 (en) | Piperidine amide derivatives as HIV attachment inhibitors | |
US8242124B2 (en) | Diketopiperidine derivatives as HIV attachment inhibitors | |
US7745463B2 (en) | Alkene piperidine derivatives as antiviral agents | |
EP2696937B1 (fr) | Dérivés de thioamide, d'amidoxine et d'amidrazone comme inhibiteurs de l'attachement du vih | |
US20160052923A1 (en) | Piperazine and homopiperazine derivatives as hiv attachment inhibitors | |
EP2978763B1 (fr) | Utilisation de dérivés 2-céto amides comme inhibiteurs de fixation du vih | |
EP2029532B1 (fr) | Pipérazine énamines utilisées en tant qu'agents antiviraux | |
EP2024355B1 (fr) | Alcène pipéridines utilisées en tant qu'agents antiviraux | |
US20130096305A1 (en) | Deuterated hiv attachment inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081031 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090206 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
DAX | Request for extension of the european patent (deleted) | ||
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 564137 Country of ref document: AT Kind code of ref document: T Effective date: 20120715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007023640 Country of ref document: DE Effective date: 20120823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 564137 Country of ref document: AT Kind code of ref document: T Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121027 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121029 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121008 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20130328 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007023640 Country of ref document: DE Effective date: 20130328 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120927 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130430 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130424 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070424 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130424 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602007023640 Country of ref document: DE Owner name: VIIV HEALTHCARE UK (NO.5) LIMITED, BRENTFORD, GB Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, PRINCETON, N.J., US Ref country code: DE Ref legal event code: R082 Ref document number: 602007023640 Country of ref document: DE Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20170322 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20170328 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20170428 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007023640 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180424 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180424 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180430 |